Form 4: Palisade Bio Insider Trades: Finley Sells Shares

John David Finley, CEO and Director of Palisade Bio, Inc., reported transactions involving the acquisition and sale of company stock, including shares to cover tax withholding obligations.

Summary

• John David Finley, CEO, CFO, and Director of Palisade Bio, Inc. (PALI), engaged in several transactions on July 6th and 7th, 2026.
• On July 6, 2026, 335,167 shares of common stock were acquired through the settlement of vested Restricted Stock Units (RSUs) granted on February 9, 2026. These RSUs vest quarterly over 10 quarters.
• Also on July 6, 2026, 133 shares were acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026.
• An adjustment was made reducing the total beneficial ownership by 66 shares due to an administrative error in a prior filing.
• On July 7, 2026, 146,798 shares were sold at a weighted average price of $2.0664 to cover tax withholding obligations related to the RSU vesting.
• Additionally, 133 shares were acquired on July 7, 2026, at a price of $0.70 per share, related to Series 2 Common Stock Purchase Warrants.
• Finley also beneficially owns 51 shares indirectly through FCW Investments, LLC, where he is the managing member.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it details insider transactions, including the sale of shares by an executive, these are largely routine events related to equity compensation and tax obligations, rather than indicative of significant positive or negative company performance.

Positives

• Vesting of Restricted Stock Units (RSUs) indicates progress in employee compensation and retention plans.
• Acquisition of shares through the Employee Stock Purchase Plan suggests employee confidence and investment in the company.
• The company has obtained stockholder approval per Nasdaq rules for warrants to become exercisable.

Negatives

• Sale of 146,798 shares to cover tax withholding obligations, while a standard practice, represents a disposition of company stock by a key executive.
• The weighted average sale price of $2.0664 for shares sold to cover taxes may indicate a lower valuation at the time of sale compared to potential future performance.

Risks

• The vesting schedule of RSUs over 10 quarters means that a significant portion of these awards will be settled over an extended period.
• The Series 2 Common Stock Purchase Warrants are subject to adjustments based on stock splits and potentially other corporate actions.
• The filing mentions an administrative error in a previous filing, highlighting potential internal control weaknesses.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the vesting schedule of RSUs implies continued employee engagement and potential future share issuances over the next 10 quarters.

Management Comments

• The sale of shares was to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for tracking insider transactions. The reported transactions, including RSU settlements and sales for tax purposes, are common for executives. The details regarding warrant adjustments reflect corporate actions typical in the biotechnology sector, such as public offerings and stock splits.

Corporate Governance

Related Party Transactions

• The acquisition of shares by John David Finley under the Employee Stock Purchase Plan on May 20, 2026, and the acquisition of shares related to Series 2 Common Stock Purchase Warrants on July 7, 2026, represent transactions between the reporting person and the issuer.
• Indirect beneficial ownership of 51 shares by John David Finley through FCW Investments, LLC, where he is the managing member, indicates a related party holding.

Stakeholder Impact

• Shareholders: Increased transparency regarding insider holdings and transactions. The sale of shares by an executive to cover taxes is a common event and may not significantly impact share price unless it represents a large portion of their holdings.
• Employees: The vesting of RSUs and participation in the ESPP can positively impact employee morale and alignment with company performance.
• Regulatory Bodies (SEC): Compliance with Section 16(a) of the Securities Exchange Act of 1934 is maintained through this filing.

Next Steps

• Continued vesting of Restricted Stock Units over the next 10 quarters.
• Potential future exercise of Series 2 Common Stock Purchase Warrants, subject to terms and conditions.
• The Reporting Person will provide further information on share sales upon request from the SEC or security holders.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Palisade Bio, PALI, John David Finley, Restricted Stock Units, RSUs, Employee Stock Purchase Plan, Stock Warrants, Beneficial Ownership, Securities Exchange Act